Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 10—October 2011
Dispatch

Yellow Fever Virus Vaccine–associated Deaths in Young Women1

Author affiliation: New York Medical College, Valhalla, New York, USA

Cite This Article

Abstract

Yellow fever vaccine–associated viscerotropic disease is a rare sequela of live-attenuated virus vaccine. Elderly persons and persons who have had thymectomies have increased susceptibility. A review of published and other data suggested a higher than expected number of deaths from yellow fever vaccine–associated viscerotropic disease among women 19–34 years of age without known immunodeficiency.

Yellow fever virus (YFV) vaccine had been considered the safest of the live-virus vaccines. Rare neurologic adverse events, called yellow fever vaccine–associated neurotropic disease (YEL-AND), have long been recognized but are seldom fatal. However, in 2001, the vaccine was found to cause a serious, frequently fatal, multisystemic illness, called yellow fever vaccine–associated viscerotropic disease (YEL-AVD), which resembles the illness it was designed to prevent (13). According to reports from the Vaccine Adverse Event Reporting System (VAERS) (www.vaers.hhs.gov), the frequency of YEL-AVD in US vaccinees was 0.4 per 100,000 doses of vaccine administered (4).

Elderly persons (4) and patients who have undergone thymectomies secondary to thymoma (5) are recognized as groups at risk for YEL-AVD. However, several case reports of YEL-AVD in young women raise concern that women of childbearing age might also be at increased risk (610).

The Study

Figure

Thumbnail of Cases of yellow fever vaccine–associated viscerotropic disease, by patient age, sex, and outcome. One woman who died and whose precise age is unknown was a young woman (P. Vasconcelos, pers. comm.) arbitrarily depicted as being 23 years of age. Data obtained from Table 36-30 in (11).

Figure. Cases of yellow fever vaccine–associated viscerotropic disease, by patient age, sex, and outcome. One woman who died and whose precise age is unknown was a young woman (P. Vasconcelos, pers. comm.)...

To investigate the possibility of age- and sex-specific risk groups, a comprehensive YEL-AVD dataset (Table 36-30 in 11), was analyzed (Figure). This dataset has the advantage of having been compiled with information that is not otherwise publicly available: data from the Centers for Disease Control and Prevention (Atlanta, GA, USA), patient charts, and vaccine manufacturers (T.P. Monath, pers. comm.).

Two concentrations of cases were evident: cases in men >60 years of age who survived and in women 19–34 years of age who died. Although selection bias may have influenced the cases reported, the sex-specific survival rates for these 2 age groups statistically differed: 21% (3/14) versus 0% (0/6) (p = 0.002 by Fisher exact test). In addition to the surprisingly low case-fatality rate for elderly men, only 2 of the 4 patients who had undergone thymectomy and had YEL-AVD died.

Searches for additional YEL-AVD cases among women of childbearing age (15–44 years) and of comparably aged men included review of published cases through PubMed (www.ncbi.nlm.nih.gov/sites/entrez) and reports from the ProMED Web site (http://apex.oracle.com/pls/otn/f?p=2400:1000:). In follow-up of a ProMED listing, 1 case was supplied by Bio-Manguinhos (Rio de Janeiro, Brazil), a producer of YFV vaccine. VAERS also was searched. Information was sought from authors of case reports. Cases listed in VAERS were excluded if another explanation for the adverse event was evident in the case description or if they contained insufficient information to classify the event as YEL-AVD.

A total of 9 fatal cases of YEL-AVD in young adults, all women, were found (Table). Six cases were included in the report by Monath et al. (11), and 3 cases were found through the author’s search. The eldest of the 9 case-patients was 34 years of age. One case listed by Monath et al. occurred in 1975 and was originally thought to be yellow fever but was documented as vaccine-related ≈2 decades later (13). This patient’s age is not known, but she was reported to be a young woman (P. Vasconcelos, pers. comm.).

Three fatal cases of possible YEL-AVD among young women reported in VAERS were excluded from the Table because information was insufficient to document the diagnosis. Two other cases of suspected YEL-AVD, 1 each in an 18-year-old man and a 24-year-old woman, occurred outside the United States. Hence, these patients could have come from regions where yellow fever was endemic and thus might have had wild-type yellow fever.

Also excluded from the Table are 2 cases reported in the published literature: 1 in a 23-year-old woman with a partial C4 deficiency and discoid lupus erythematosis hospitalized with severe YEL-AND and YEL-AVD who survived (14) and 1 in a 43-year-old woman with systemic lupus erythematosus who died (10). The first was excluded because she survived, had clinical features that included YEL-AND, and had known immunodeficiency. For the second patient, a history of disseminated lupus erythematosis, the relatively long interval (30 days) until death (in contrast to the 9–14 days in the other women), and her older age suggest that her susceptibility to the vaccine differed from those listed in the Table.

In several investigations of YEL-AVD cases, extensive sequence analyses did not indicate any substantial evidence of reversion of the vaccine to virulence (1,10). Two varieties of YFV vaccine are available: the 17DD vaccine produced in Brazil and used in South America and the 17D-204 vaccine (YF-Vax, Sanofi Pasteur, Swiftwater, PA, USA; and Stamaril, Sanofi Pasteur, Lyon, France) used elsewhere. Six cases listed in the Table occurred in 17DD vaccine recipients in South America, and 3 occurred in persons who received 17D-204 as prospective travelers.

The limited racial information available indicates that cases were not confined to persons of any particular racial group. Of 3 case-patients for whom racial information was available, 1 each was described as Caucasian (8), black (2), and of Pacific Islander ancestry (7).

Despite the known association of thymectomy with YEL-AVD, the only observation on possible thymic disease in the reports of the 9 cases is the statement that, at autopsy of a 22-year-old woman from the United States, the thymus was replaced by fat (Table 36-30 in 11). However, the accuracy of the finding should be considered in the context that, at surgery, experienced cardiothoracic surgeons may have difficulty in distinguishing thymus from adipose tissue (R.L. Berger, pers. comm.) and that the thymus was not examined histologically (R.V. Ridenour, III, pers. comm.). Because the thymus may be difficult to separate from surrounding adipose tissue and is infrequently a source of disease, pathologists, at least in the United States, do not routinely examine it histologically at autopsy (I. Argani, pers. comm.). Thymic deficiencies such as Sutton thymic dysplasia (fatal viral infection in young women with a dysplastic thymus) (15) have yet to be excluded.

Conclusions

Although accurate denominators are not available for calculating age- and sex-specific incidence of YEL-AVD, the number of fatal YEL-AVD cases among women of childbearing age appears to be higher than expected. Further investigation should include ascertainment of family history; exploration of contraceptive medications or occult pregnancy as possible predisposing factors; examination of the thymus at postmortem, including thymus weight and histology; further evaluation of possible complement defects; and evaluation of any associations with autoimmune disease.

Dr Seligman is a research professor in the Department of Microbiology and Immunology, New York Medical College. His current research interests include flaviviruses with emphasis on the safety of flavivirus vaccines.

Top

Acknowledgment

The author thanks F.H. Moy for statistical assistance and J. Dinardi for computer aid with the figure. R. Menezes-Martins kindly provided data on a previously unreported case.

Top

References

  1. Martin  M, Tsai  TF, Cropp  B, Chang  GJ, Holmes  DA, Tseng  J, Fever and multisystem organ failure associated with 17D–204 yellow fever vaccination: a report of four cases. Lancet. 2001;358:98104. DOIPubMedGoogle Scholar
  2. Vasconcelos  PF, Luna  EJ, Galler  R, Silva  LJ, Coimbra  TL, Barros  VL, Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358:917. DOIPubMedGoogle Scholar
  3. Chan  RC, Penney  DJ, Little  D, Carter  IW, Roberts  JA, Rawlinson  WD. Hepatitis and death following vaccination with 17D–204 yellow fever vaccine. Lancet. 2001;358:1212. DOIPubMedGoogle Scholar
  4. Lindsey  NP, Schroeder  BA, Miller  ER, Braun  MM, Hinckley  AF, Marano  N, Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:607782. DOIPubMedGoogle Scholar
  5. Barwick  R. History of thymoma and yellow fever vaccination. Lancet. 2004;364:936. DOIPubMedGoogle Scholar
  6. Vasconcelos  PF, Bryant  JE, da Rosa  TP, Tesh  RB, Rodrigues  SG, Barrett  AD. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis. 2004;10:157884.PubMedGoogle Scholar
  7. Gerasimon  G, Lowry  K. Rare case of fatal yellow fever vaccine–associated viscerotropic disease. South Med J. 2005;98:6536. DOIPubMedGoogle Scholar
  8. Doblas  A, Domingo  C, Bae  HG, Bohorquez  CL, de Ory  F, Niedrig  M, Yellow fever vaccine–associated viscerotropic disease and death in Spain. J Clin Virol. 2006;36:1568. DOIPubMedGoogle Scholar
  9. Belsher  JL, Gay  P, Brinton  M, DellaValla  J, Ridenour  R, Lanciotti  R, Fatal multiorgan failure due to yellow fever vaccine–associated viscerotropic disease. Vaccine. 2007;25:84805. DOIPubMedGoogle Scholar
  10. Whittembury  A, Ramirez  G, Hernandez  H, Ropero  AM, Waterman  S, Ticona  M, Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009;27:597481. DOIPubMedGoogle Scholar
  11. Monath  TP, Cetron  MS, Teuwen  DE. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines, 5th ed. Philadelphia: Saunders; 2008. p. 959–1055.
  12. Struchiner  CJ, Luz  PM, Dourado  I, Sato  HK, Aguiar  SG, Ribeiro  JG, Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect. 2004;132:93946. DOIPubMedGoogle Scholar
  13. Engel  AR, Vasconcelos  PF, McArthur  MA, Barrett  AD. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine. 2006;24:28039. DOIPubMedGoogle Scholar
  14. Silva  ML, Espirito-Santo  LR, Martins  MA, Silveira-Lemos  D, Peruhype-Magalhaes  V, Caminha  RC, Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol. 2010;17:11826. DOIPubMedGoogle Scholar
  15. Sutton  AL, Smithwick  EM, Seligman  SJ, Kim  DS. Fatal disseminated herpesvirus hominis type 2 infection in an adult with associated thymic dysplasia. Am J Med. 1974;56:54553. DOIPubMedGoogle Scholar

Top

Figure
Table

Top

Cite This Article

DOI: 10.3201/eid1710.101789

1Data previously presented at a National Institutes of Health–supported Northeast Biodefense Center conference, New Paltz, New York, USA, November 2, 2010.

Table of Contents – Volume 17, Number 10—October 2011

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Stephen J. Seligman, Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA

Send To

10000 character(s) remaining.

Top

Page created: September 23, 2011
Page updated: September 23, 2011
Page reviewed: September 23, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external